We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Anticancer Therapies – Products

Type I IFNs: First-Line of Defense Against Viral Infections and Neoplastic Transformation content piece image
Product
Advertisement

Type I IFNs: First-Line of Defense Against Viral Infections and Neoplastic Transformation

Sino Biological has developed an array of high-quality Proteins, Antibodies, Genes, Lysate, and qPCR Primer Pairs to support the study of IFN-Is.
Avacta Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin content piece image
Product News

Avacta Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group plc announces that the first-in-human Phase I trial of AVA6000 Pro-doxorubicin will advance to the third dose cohort following a positive review of the safety data from the dosing of the second cohort.
Expansion of Specific Lymphocyte Populations content piece image
App Note / Case Study

Expansion of Specific Lymphocyte Populations

Expansion of Specific Lymphocyte Populations With 4Cell® Nutri-T Xeno-Free, Serum-Free Medium

The success of CAR T-cell therapy requires efficient expansion of specific subpopulations of patient-derived immune cells.
PD-1/PD-L1 Combination Therapy in Cancer Treatment content piece image
Whitepaper

PD-1/PD-L1 Combination Therapy in Cancer Treatment

Cancer immunotherapy, especially the use of immune checkpoint inhibitors, has been successful in improving the treatment landscape of malignancies.
SomaLogic Announces License Agreement With OncoHost for the Development of Precision Cancer Diagnostics content piece image
Product News

SomaLogic Announces License Agreement With OncoHost for the Development of Precision Cancer Diagnostics

SomaLogic has announced it has signed a licensing agreement with OncoHost.
Therapeutic Targets in CAR NK-Cell Therapy content piece image
Product
Advertisement

Therapeutic Targets in CAR NK-Cell Therapy

Natural killer (NK) cells are immune cells capable of killing target cells and can be genetically modified to express chimeric antigen receptors (CARs). CAR NK-cell therapy is an innovative type of cancer immunotherapy for solid tumors and hematological malignancies.
Quantifying T Cell Response in 3D Tumor Spheroids Using Advanced Flow Cytometry Workflows content piece image
App Note / Case Study

Quantifying T Cell Response in 3D Tumor Spheroids Using Advanced Flow Cytometry Workflows

Discovery of novel immunotherapies that specifically target and enhance the T cell response against cancer is a rapidly expanding research area. Robust and relevant in vitro models for evaluation of these immunotherapies is essential throughout their development.
Research Tools for Anti-Cancer Drug Targets content piece image
Whitepaper

Research Tools for Anti-Cancer Drug Targets

Currently, various treatments are available to cancer patients, such as chemotherapy, targeted therapy and immunotherapy. Targeted therapy is a type of precision medicine that targets the proteins that control the growth, division and spread of cancer cells.
AMSBIO Expands EU Operations content piece image
Product News

AMSBIO Expands EU Operations

Life science specialists, AMSBIO, have made a new strategic investment to enhance the level of support to its sizeable and growing base of customers across the European Union.
Protein Biomarkers Show Promise in Predicting Patient Response to Cancer Immunotherapies content piece image
Whitepaper

Protein Biomarkers Show Promise in Predicting Patient Response to Cancer Immunotherapies

Cancer immunotherapy relies on activating or enhancing the antitumor immune response and has taken a central position in cancer treatment modalities. However, not all patients respond to immunotherapy, and combination immunotherapies increase cost of treatment and heighten the risk for toxicity-related adverse events.
Advertisement